Abstracts tagged "joint destruction"

Abstract Number: 343 • 2012 ACR/ARHP Annual Meeting
Functional Impairment in an Animal Model for Rheumatoid Arthritis Assessed As Changes in Gait Is Due to Joint Destruction but Not Synovial Inflammation Per Se
Gregor Bauer¹, Constantin Aschauer¹, Birgit Niederreiter², Josef S. Smolen³, Kurt Redlich² and Silvia Hayer², ¹Dep. of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: To investigate the individual impact of synovial inflammation, subchondral bone erosion or cartilage damage on functional impairment in an animal model of Rheumatoid Arthritis…
Abstract Number: 204 • 2012 ACR/ARHP Annual Meeting
Characterization of Joint Disease in Mucopolysaccharidosis Type I Mice and the Effects of Enzyme Replacement Therapy
Patricia Oliveira¹, Guilherme Baldo², Fabiana Mayer², Barbara Martinelli², Luise Meurer³, Roberto Giugliani², Ursula Matte² and Ricardo M. Xavier⁴, ¹Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ²Genetics, Hospital de Clinicas de Porto Alegre, ³Pathology, Hospital de Clinicas de Porto Alegre, ⁴Rheumatology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil
Background/Purpose: Mucopolysaccharidosis type I (MPS I) is a lysosomal disorder caused by deficiency of alpha-L-iduronidase, which leads to storage of glycosaminoglycans. Patients with MPS I…
Abstract Number: 111 • 2012 ACR/ARHP Annual Meeting
Ultrasound Measurement of Metacarpal Cartilage Thickness Correlates with Joint Space Narrowing in the Metacarphalangeal Joints of Patients with Rheumatoid Arthritis
Peter Mandl¹, Helga Radner², Gabriela Supp³, Peter V. Balint⁴, Daniel Aletaha³ and Josef S. Smolen⁵, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Rheumatology, National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁵Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: To correlate cartilage thickness as measured by ultrasound (US) with joint space narrowing as measured by conventional radiography in the metacarpophalangeal (MCP) joints of…
Abstract Number: 2133 • 2012 ACR/ARHP Annual Meeting
Relationship Between Clinical Response and Radiographic Outcomes in Patients with Moderate Rheumatoid Arthritis
Josef S. Smolen¹, Ronald F. van Vollenhoven², Andrew S. Koenig³, Ronald Pedersen³, Annette Szumski⁴ and Eustratios Bananis⁴, ¹Department of Rheumatology, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Unit for Clinical Trial Therapy research, The Karolinska Institute, Stockholm, Sweden, ³Specialty Care, Pfizer Inc, Collegeville, PA, ⁴Specialty Care, Pfizer Inc., Collegeville, PA
Background/Purpose: Clinical evidence has established the importance of early, intensive treatment of rheumatoid arthritis (RA) to decrease disease activity and prevent joint damage.1 The objective…
Abstract Number: 2114 • 2012 ACR/ARHP Annual Meeting
Joint Damage Progression in Rheumatoid Arthritis: Role of the HLA-DRB1 Shared Epitope and Anti-CCP
Jose Felix Restrepo¹, Inmaculada del Rincon¹, Roy W. Haas², Daniel F. Battafarano³ and Agustin Escalante², ¹Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ²Dept. of Medicine-Rheumatology, University of Texas Health Science Center at San Antonio, San Antonio, TX, ³Medicine / MCHE-MDR, Brooke Army Medical Ctr, San Antonio, TX
Background/Purpose: The HLA-DRB1 shared epitope (SE) and antibodies to cyclic citrullinated peptides (anti-CCP) are important to the susceptibility to rheumatoid arthritis (RA), and are thought…
Abstract Number: 2118 • 2012 ACR/ARHP Annual Meeting
Validation of Prognostic Biomarkers for RA: Testing of 14-3-3 Eta According to the Omeract Soluble Biomarker Criteria
Walter P. Maksymowych¹, Désirée van der Heijde², R. Landewe³, George A. Wells⁴, Joan M. Bathon⁵, Clifton O. Bingham III⁶, Vivian P. Bykerk⁷, Mikkel Ostergaard⁸, Hilde B. Hammer⁹, Maarten Boers¹⁰, Paul Peter Tak¹¹, Oliver M. FitzGerald¹², Christopher T. Ritchlin¹³, Dafna D. Gladman¹⁴, Philip J. Mease¹⁵, Dirkjan van Schaardenburg¹⁶, Marina Backhaus¹⁷, Bernard Combe¹⁸, Gianfranco Ferraccioli¹⁹ and Anthony Marotta²⁰, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands, ⁴Epidemiology & Community Med, Univ of Ottawa Faculty of Med, Ottawa, ON, Canada, ⁵Columbia University, New York, NY, ⁶Rheumatology, Johns Hopkins University, Baltimore, MD, ⁷Rheumatology, Hospital for Special Surgery, New York, NY, ⁸Dept of Rheumatology RM, Copenhagen University Hospital, Glostrup, Denmark, ⁹Dept of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ¹⁰Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹²Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland, ¹³Allergy, Immunology and Rheumatology, University of Rochester, Rochester, NY, ¹⁴Division of Rheumatology, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁵Swedish Rheumatology Research Group, Seattle, WA, ¹⁶Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ¹⁷Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ¹⁸Rheumatology, Hopital Lapeyronie, Montpellier, France, ¹⁹Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ²⁰Augurex Life Sciences Corp, North Vancouver, BC, Canada
Background/Purpose: The OMERACT soluble biomarker sub-committee has published validation criteria related to truth, discrimination and feasibility for biomarkers reflecting structural damage1. The large majority of…
Abstract Number: 2092 • 2012 ACR/ARHP Annual Meeting
No Significant Effect of Hepatitis B Virus Infection On Disease Activity, Synovitis or Joint Destruction in Rheumatoid Arthritis
Chan Juan Zou, Yan Hua Li, Ying Qian Mo, Lang Jing Zhu, Dong Hui Zheng, Jian Da Ma, Xia Ouyang and Lie Dai, Division of Rheumatology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China
Background/Purpose: The prevalence of chronic hepatitis B virus (HBV) infection is high in China. 4% patients with HBV infection can present with polyarthritis and positive…
Abstract Number: 1849 • 2012 ACR/ARHP Annual Meeting
Value of Matrices Developed to Identify Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression Despite Methotrexate Therapy: A Comparison of Their Performance in the Early Rheumatoid Arthritis Espoir Cohort
Bruno Fautrel¹, Benjamin Granger², Bernard Combe³, Francis Guillemin⁴, Alain Saraux⁵ and Xavier Le Loët⁶, ¹Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France, ²Biostatistics - GRC08-EEMOIS, Université Pierre et Marie Curie - Paris 6 ; AP-HP, Paris, France, ³CHU Lapeyronie, Montpellier, France, ⁴Hopitaux de Brabois, Nancy, France, ⁵Department of rheumatology and unit of immunology (EA 2216), Université Brest Occidentale, Brest, France, ⁶Rheumatology, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France
Background/Purpose: Rapid radiographic progression (RRP) – i.e., increase of the Sharp/van der Heijde score (vSHS) ≥ 5 points during the 1st year – is a…
Abstract Number: 1040 • 2012 ACR/ARHP Annual Meeting
Combined High-Resolution Single Photon Emission Computed Tomography and Magnetic Resonance Imaging for Therapy Monitoring in Rheumatoid Arthritis
Philipp Sewerin¹, Christian Buchbender², Katalin Mattes-György³, Falk Miese², Hans-Jörg Wittsack², Christof Specker⁴, Gerald Antoch², Matthias Schneider⁵, Axel Scherer² and Ben Ostendorf¹, ¹Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Düsseldorf, Germany, ²Diagnostic and Interventional Radiology, Heinrich-Heine-University, Düsseldorf, Germany, ³Nuclear Medicine, Heinrich-Heine-University, Düsseldorf, Germany, ⁴Department of rheumatology and clinical immunology, Hospital Essen Sued, Essem, Germany, ⁵Endocrinology, Diabetology and Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: To evaluate whether combined multi-pinhole single photon emission computed tomography (MPH-SPECT) with technetium-99m-labelled disphosphonates (Tc99m-DPD) and magnetic resonance imaging (MRI) detect changes in inflammation…
Abstract Number: 1022 • 2012 ACR/ARHP Annual Meeting
Imaging of Ankle Joints by MRI in Murine Models of Inflammatory Arthritis
Shawn M. Rose¹, Harris R. Perlman², Emily Alex Waters³ and Thomas Meade³, ¹Department of Medicine, Division of Rheumatology, Northwestern University, Chicago, IL, ²Feinberg School of Medicine, Northwestern University, Chicago, IL, ³Chemistry of Life Processes Institute, Northwestern University, Evanston, IL
Background/Purpose: One of the fundamental shortcomings in the field of experimental rheumatology is the inability to non-invasively monitor the development of inflammatory arthritis longitudinally. Magnetic…
Abstract Number: 894 • 2012 ACR/ARHP Annual Meeting
Genetic Variants in the IL-4 and IL-4 Receptor Genes in Association with the Severity of Joint Damage in Rheumatoid Arthritis: A Study in Seven Cohorts
A. Krabben¹, A. G. Wilson², R. Knevel¹, A. Zhernakova³, E. Brouwer³, E. Lindqvist⁴, T. Saxne⁴, G. Stoeken-Rijsbergen¹, J. A. B. van Nies¹, D. P. C. de Rooy¹, T.W.J. Huizinga¹, B. P. C. Koeleman⁵, R. E. M. Toes¹, P. K. Gregersen⁶ and A. H. M. van der Helm-van Mil¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Infection & Immunity, University of Sheffield, Sheffield, United Kingdom, ³Rheumatology and Clinical Immunology, University of Groningen, University Medical Center, Groningen, Netherlands, ⁴Rheumatology, Lund University, Lund, Sweden, ⁵Medical Genetics, University Medical Center Utrecht, Utrecht, Netherlands, ⁶Genomics and Human Genetics, Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY
Background/Purpose: The severity of RA is reflected by the severity of radiological joint destruction. It is highly variable between patients and up to 58% of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].